Aurinia Net Tangible Assets vs Net Receivables Analysis

AUPH Stock

USD 10.49 1.25 13.53%

Aurinia Pharmaceuticals financial indicator trend analysis is way more than just evaluating Aurinia Pharmaceuticals prevailing accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Aurinia Pharmaceuticals is a good investment. Please check the relationship between Aurinia Pharmaceuticals Net Tangible Assets and its Net Receivables accounts. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Aurinia Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in american community survey.

For more detail on how to invest in Aurinia Stock please use our How to Invest in Aurinia Pharmaceuticals guide.

Net Tangible Assets vs Net Receivables

Net Tangible Assets vs Net Receivables Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Aurinia Pharmaceuticals Net Tangible Assets account and Net Receivables. At this time, the significance of the direction appears to have strong relationship.

The correlation between Aurinia Pharmaceuticals' Net Tangible Assets and Net Receivables is 0.77. Overlapping area represents the amount of variation of Net Tangible Assets that can explain the historical movement of Net Receivables in the same time period over historical financial statements of Aurinia Pharmaceuticals, assuming nothing else is changed. The correlation between historical values of Aurinia Pharmaceuticals' Net Tangible Assets and Net Receivables is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Net Tangible Assets of Aurinia Pharmaceuticals are associated (or correlated) with its Net Receivables. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Net Receivables has no effect on the direction of Net Tangible Assets i.e., Aurinia Pharmaceuticals' Net Tangible Assets and Net Receivables go up and down completely randomly.

Correlation Coefficient

0.77

Relationship Direction	Positive
Relationship Strength	Significant

View All Relationships

Net Tangible Assets

The total assets of a company minus any intangible assets such as patents, copyrights, and goodwill; it represents the physical assets of a company.

Net Receivables

Most indicators from Aurinia Pharmaceuticals' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Aurinia Pharmaceuticals current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Aurinia Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in american community survey.

For more detail on how to invest in Aurinia Stock please use our How to Invest in Aurinia Pharmaceuticals guide.As of now, Aurinia Pharmaceuticals' Enterprise Value Multiple is increasing as compared to previous years. The Aurinia Pharmaceuticals' current Enterprise Value is estimated to increase to about 1.5 B, while Sales General And Administrative To Revenue is projected to decrease to 1.21.

	2022	2023	2024	2025 (projected)
Total Operating Expenses	239.8M	253.1M	211.6M	222.2M
Cost Of Revenue	5.7M	14.1M	28.2M	29.7M

Total Operating Expenses Cost Of Revenue

Aurinia Pharmaceuticals fundamental ratios Correlations

	Total Assets	Short Long Term Debt Total	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Property Plant And Equipment Net	Current Deferred Revenue	Net Debt	Retained Earnings	Accounts Payable	Non Current Assets Total	Other Assets	Cash And Short Term Investments	Net Receivables	Common Stock Shares Outstanding	Non Current Liabilities Total	Inventory	Other Current Assets	Other Stockholder Equity	Total Liab	Property Plant And Equipment Gross	Total Current Assets	Short Term Debt	Intangible Assets	Cash	Non Currrent Assets Other
Total Assets		0.69	0.9	0.87	0.98	0.7	0.69	-0.3	-0.96	0.55	0.77	0.91	0.98	0.8	0.97	0.8	0.91	0.94	0.87	0.86	0.7	0.99	0.56	-0.32	0.54	0.02
Short Long Term Debt Total	0.69		0.86	0.9	0.55	0.99	0.22	0.35	-0.75	0.42	0.98	0.77	0.52	0.89	0.67	0.95	0.87	0.58	0.9	0.95	0.99	0.59	0.89	-0.3	-0.07	-0.19
Other Current Liab	0.9	0.86		0.99	0.82	0.89	0.55	0.1	-0.91	0.39	0.92	0.97	0.79	0.96	0.85	0.86	0.95	0.83	0.98	0.96	0.89	0.85	0.65	-0.4	0.16	-0.02
Total Current Liabilities	0.87	0.9	0.99		0.78	0.92	0.48	0.16	-0.9	0.43	0.94	0.95	0.75	0.98	0.83	0.89	0.96	0.81	0.99	0.98	0.93	0.81	0.69	-0.39	0.11	-0.07
Total Stockholder Equity	0.98	0.55	0.82	0.78		0.57	0.74	-0.43	-0.93	0.53	0.66	0.86	1.0	0.69	0.96	0.69	0.83	0.93	0.78	0.76	0.57	1.0	0.45	-0.29	0.64	0.07
Property Plant And Equipment Net	0.7	0.99	0.89	0.92	0.57		0.26	0.37	-0.75	0.37	0.98	0.8	0.54	0.91	0.66	0.94	0.88	0.6	0.92	0.96	1.0	0.61	0.87	-0.37	-0.08	-0.21
Current Deferred Revenue	0.69	0.22	0.55	0.48	0.74	0.26		-0.43	-0.55	0.21	0.36	0.6	0.73	0.43	0.59	0.29	0.45	0.57	0.42	0.4	0.26	0.72	0.08	-0.22	0.54	0.13
Net Debt	-0.3	0.35	0.1	0.16	-0.43	0.37	-0.43		0.15	-0.34	0.27	0.07	-0.48	0.25	-0.32	0.09	0.04	-0.27	0.18	0.13	0.37	-0.39	0.32	-0.14	-0.96	0.0
Retained Earnings	-0.96	-0.75	-0.91	-0.9	-0.93	-0.75	-0.55	0.15		-0.6	-0.81	-0.93	-0.91	-0.84	-0.96	-0.84	-0.94	-0.95	-0.93	-0.89	-0.75	-0.94	-0.63	0.28	-0.4	-0.09
Accounts Payable	0.55	0.42	0.39	0.43	0.53	0.37	0.21	-0.34	-0.6		0.39	0.39	0.56	0.39	0.69	0.58	0.58	0.6	0.46	0.51	0.37	0.55	0.33	0.0	0.49	-0.02
Non Current Assets Total	0.77	0.98	0.92	0.94	0.66	0.98	0.36	0.27	-0.81	0.39		0.84	0.62	0.9	0.74	0.93	0.9	0.65	0.93	0.96	0.98	0.69	0.85	-0.27	0.02	-0.16
Other Assets	0.91	0.77	0.97	0.95	0.86	0.8	0.6	0.07	-0.93	0.39	0.84		0.83	0.93	0.87	0.77	0.93	0.89	0.96	0.89	0.8	0.88	0.59	-0.41	0.17	0.11
Cash And Short Term Investments	0.98	0.52	0.79	0.75	1.0	0.54	0.73	-0.48	-0.91	0.56	0.62	0.83		0.66	0.95	0.68	0.81	0.93	0.75	0.73	0.53	0.99	0.42	-0.29	0.68	0.06
Net Receivables	0.8	0.89	0.96	0.98	0.69	0.91	0.43	0.25	-0.84	0.39	0.9	0.93	0.66		0.76	0.86	0.92	0.76	0.96	0.95	0.91	0.74	0.65	-0.4	0.01	-0.04
Common Stock Shares Outstanding	0.97	0.67	0.85	0.83	0.96	0.66	0.59	-0.32	-0.96	0.69	0.74	0.87	0.95	0.76		0.79	0.9	0.94	0.85	0.84	0.66	0.97	0.53	-0.23	0.55	0.06
Non Current Liabilities Total	0.8	0.95	0.86	0.89	0.69	0.94	0.29	0.09	-0.84	0.58	0.93	0.77	0.68	0.86	0.79		0.93	0.72	0.9	0.97	0.94	0.73	0.86	-0.3	0.2	-0.19
Inventory	0.91	0.87	0.95	0.96	0.83	0.88	0.45	0.04	-0.94	0.58	0.9	0.93	0.81	0.92	0.9	0.93		0.9	0.97	0.97	0.88	0.86	0.72	-0.4	0.23	-0.08
Other Current Assets	0.94	0.58	0.83	0.81	0.93	0.6	0.57	-0.27	-0.95	0.6	0.65	0.89	0.93	0.76	0.94	0.72	0.9		0.84	0.79	0.6	0.94	0.44	-0.36	0.48	0.12
Other Stockholder Equity	0.87	0.9	0.98	0.99	0.78	0.92	0.42	0.18	-0.93	0.46	0.93	0.96	0.75	0.96	0.85	0.9	0.97	0.84		0.97	0.92	0.82	0.72	-0.41	0.09	-0.02
Total Liab	0.86	0.95	0.96	0.98	0.76	0.96	0.4	0.13	-0.89	0.51	0.96	0.89	0.73	0.95	0.84	0.97	0.97	0.79	0.97		0.96	0.79	0.79	-0.36	0.16	-0.13
Property Plant And Equipment Gross	0.7	0.99	0.89	0.93	0.57	1.0	0.26	0.37	-0.75	0.37	0.98	0.8	0.53	0.91	0.66	0.94	0.88	0.6	0.92	0.96		0.61	0.86	-0.37	-0.08	-0.21
Total Current Assets	0.99	0.59	0.85	0.81	1.0	0.61	0.72	-0.39	-0.94	0.55	0.69	0.88	0.99	0.74	0.97	0.73	0.86	0.94	0.82	0.79	0.61		0.48	-0.32	0.61	0.05
Short Term Debt	0.56	0.89	0.65	0.69	0.45	0.87	0.08	0.32	-0.63	0.33	0.85	0.59	0.42	0.65	0.53	0.86	0.72	0.44	0.72	0.79	0.86	0.48		-0.25	-0.05	-0.17
Intangible Assets	-0.32	-0.3	-0.4	-0.39	-0.29	-0.37	-0.22	-0.14	0.28	0.0	-0.27	-0.41	-0.29	-0.4	-0.23	-0.3	-0.4	-0.36	-0.41	-0.36	-0.37	-0.32	-0.25		0.03	0.21
Cash	0.54	-0.07	0.16	0.11	0.64	-0.08	0.54	-0.96	-0.4	0.49	0.02	0.17	0.68	0.01	0.55	0.2	0.23	0.48	0.09	0.16	-0.08	0.61	-0.05	0.03		-0.07
Non Currrent Assets Other	0.02	-0.19	-0.02	-0.07	0.07	-0.21	0.13	0.0	-0.09	-0.02	-0.16	0.11	0.06	-0.04	0.06	-0.19	-0.08	0.12	-0.02	-0.13	-0.21	0.05	-0.17	0.21	-0.07

Click cells to compare fundamentals

Aurinia Pharmaceuticals Account Relationship Matchups

Aurinia Pharmaceuticals fundamental ratios Accounts

	2020	2021	2022	2023	2024	2025 (projected)
Total Assets	463.7M	543.4M	470.9M	548.1M	550.6M	578.2M
Other Current Liab	27.8M	33.8M	37.4M	51.8M	66.5M	69.8M
Total Current Liabilities	32.0M	40.6M	46.1M	77.2M	97.8M	102.7M
Total Stockholder Equity	407.8M	479.1M	405.4M	378.0M	377.5M	396.4M
Property Plant And Equipment Net	10.3M	9.8M	8.6M	116.6M	98.9M	103.8M
Current Deferred Revenue	21.4M	31.1M	3.1M	4.8M	11.0M	11.6M
Net Debt	(263.9M)	(223.2M)	(86.1M)	48.7M	(4.1M)	(4.3M)
Retained Earnings	(575.2M)	(756.1M)	(864.3M)	(942.3M)	(936.6M)	(889.7M)
Accounts Payable	2.6M	3.9M	3.1M	4.3M	5.2M	3.2M
Non Current Assets Total	44.2M	30.0M	28.3M	123.3M	104.0M	109.3M
Other Assets	209K	5.7M	11.8M	13.3M	15.3M	16.1M
Cash And Short Term Investments	398.3M	466.1M	389.4M	350.5M	358.5M	376.4M
Net Receivables	1.0M	15.4M	13.5M	24.1M	36.5M	38.4M
Common Stock Shares Outstanding	118.5M	129.4M	141.9M	143.2M	146.2M	153.5M
Liabilities And Stockholders Equity	463.7M	543.4M	470.9M	548.1M	550.6M	578.2M
Non Current Liabilities Total	23.9M	23.6M	19.3M	92.9M	75.4M	79.2M
Other Current Assets	7.2M	12.5M	14.9M	10.5M	12.3M	13.0M
Other Stockholder Equity	39.4M	59.0M	85.5M	120.8M	127.0M	133.3M
Total Liab	55.9M	64.3M	65.4M	170.1M	173.2M	181.8M
Property Plant And Equipment Gross	10.3M	9.8M	8.6M	118.5M	101.4M	106.5M
Total Current Assets	419.4M	513.3M	442.5M	424.8M	446.6M	468.9M
Short Term Debt	1.6M	2.1M	1.9M	42.5M	15.1M	15.8M
Intangible Assets	9.3M	8.4M	6.4M	5.0M	4.4M	6.9M
Cash	272.4M	231.9M	94.2M	48.9M	83.4M	67.3M
Non Currrent Assets Other	247K	11.8M	13.3M	1.5M	823K	781.9K
Other Liab	14.4M	16.3M	16.0M	12.2M	14.0M	7.3M
Net Tangible Assets	289.7M	398.4M	470.7M	399.0M	458.9M	481.8M
Common Stock Total Equity	504.7M	790.5M	944.3M	1.2B	1.4B	1.4B
Short Term Investments	126.0M	234.2M	295.2M	301.6M	275.0M	288.8M
Common Stock	944.3M	1.2B	1.2B	1.2B	1.2B	1.2B
Property Plant Equipment	93K	4.8M	9.8M	8.6M	7.7M	8.1M
Capital Surpluse	24.7M	23.7M	39.4M	59.0M	67.9M	71.3M
Non Current Liabilities Other	1.6M	16.0M	12.2M	10.9M	11.1M	9.2M
Net Invested Capital	407.8M	479.1M	405.4M	378.0M	377.5M	357.4M

Currently Active Assets on Macroaxis

USOI	Credit Suisse X Links
ULTY	Tidal Trust II
CONY	YieldMax N Option
BCAT	BlackRock Capital Allocation
PDI	Pimco Dynamic Income

When determining whether Aurinia Pharmaceuticals offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Aurinia Pharmaceuticals' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Aurinia Pharmaceuticals Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Aurinia Pharmaceuticals Stock:

How To Invest In Aurinia

Details

Is Aurinia Stock a good investment?

Details

What is Aurinia Pharmaceuticals' Net Worth?

Details

Largest Biotechnology Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Aurinia Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in american community survey.

For more detail on how to invest in Aurinia Stock please use our How to Invest in Aurinia Pharmaceuticals guide.

You can also try the Money Flow Index module to determine momentum by analyzing Money Flow Index and other technical indicators.

Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Aurinia Pharmaceuticals. If investors know Aurinia will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Aurinia Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Quarterly Earnings Growth

30.667

Earnings Share

0.43

Revenue Per Share

1.861

Quarterly Revenue Growth

0.224

Return On Assets

0.0769

The market value of Aurinia Pharmaceuticals is measured differently than its book value, which is the value of Aurinia that is recorded on the company's balance sheet. Investors also form their own opinion of Aurinia Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Aurinia Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Aurinia Pharmaceuticals' market value can be influenced by many factors that don't directly affect Aurinia Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Aurinia Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Aurinia Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Aurinia Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2025 Macroaxis LLC

Aurinia Net Tangible Assets vs Net Receivables Analysis

Net Tangible Assets vs Net Receivables

Net Tangible Assets vs Net Receivables Correlation Analysis

Correlation Coefficient

Net Tangible Assets

Net Receivables

Aurinia Pharmaceuticals fundamental ratios Correlations

Aurinia Pharmaceuticals Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Aurinia Pharmaceuticals fundamental ratios Accounts

Currently Active Assets on Macroaxis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Cash And Short Term Investments	+ 1.0	Total Stockholder Equity
Total Current Assets	+ 1.0	Total Stockholder Equity
Property Plant And Equipment Gross	+ 1.0	Property Plant And Equipment Net
Total Current Assets	+ 0.99	Total Assets
Property Plant And Equipment Net	+ 0.99	Short Long Term Debt Total
Property Plant And Equipment Gross	+ 0.99	Short Long Term Debt Total

Common Stock Shares Outstanding	- 0.96	Retained Earnings
Cash	- 0.96	Net Debt
Retained Earnings	- 0.96	Total Assets
Other Current Assets	- 0.95	Retained Earnings
Total Current Assets	- 0.94	Retained Earnings
Inventory	- 0.94	Retained Earnings